Paper38579288
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
Ng BD and 15 others. Blood, 2024. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Papers, record 38579288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38579288
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Interleukin-18 | Major topic |
| Immunotherapy, Adoptive | Major topic |
| B-Cell Maturation Antigen | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Receptors, Chimeric Antigen | |
| Disease Models, Animal | |
| Antigens, Neoplasm | |
| T-Lymphocytes | |
| Cell Line, Tumor |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HL164902 | NHLBI NIH HHS | United States | R01HL164902 | PubMed and NIH | NIH RePORTER |
| P01 CA023766 | NCI NIH HHS | United States | P01CA023766 | PubMed and NIH | NIH RePORTER |
| R01 HL147584 | NHLBI NIH HHS | United States | R01HL147584 | PubMed and NIH | NIH RePORTER |
| R35 CA284024 | NCI NIH HHS | United States | R35CA284024 | PubMed and NIH | NIH RePORTER |
| P50 CA254838 | NCI NIH HHS | United States | P50CA254838 | PubMed and NIH | NIH RePORTER |
| K08 CA252157 | NCI NIH HHS | United States | K08CA252157 | PubMed and NIH | NIH RePORTER |
| L30 CA209765 | NCI NIH HHS | United States | L30CA209765 | PubMed and NIH | NIH RePORTER |
| R01 CA228308 | NCI NIH HHS | United States | R01CA228308 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| P01 AG052359 | NIA NIH HHS | United States | P01AG052359 | PubMed and NIH | NIH RePORTER |
References90
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20643337 | Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. | Immunity | 2010 | https://conductscience.org/library/papers/20643337 | PubMed |
| 2 | 28225754 | Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. | Nature | 2017 | https://conductscience.org/library/papers/28225754 | PubMed |
| 3 | 33837065 | IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33837065 | PubMed |
| 4 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 5 | 37653344 | Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. | Nat Med | 2023 | https://conductscience.org/library/papers/37653344 | PubMed |
| 6 | 26084029 | GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. | Immunity | 2015 | https://conductscience.org/library/papers/26084029 | PubMed |
| 7 | 36416874 | CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36416874 | PubMed |
| 8 | 27571406 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27571406 | PubMed |
| 9 | 32034142 | CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. | Nat Commun | 2020 | https://conductscience.org/library/papers/32034142 | PubMed |
| 10 | 33020647 | Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. | Nat Med | 2020 | https://conductscience.org/library/papers/33020647 | PubMed |
| 11 | 35017485 | A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. | Nat Commun | 2022 | https://conductscience.org/library/papers/35017485 | PubMed |
| 12 | 23640482 | Transcriptional control of macrophage polarization. | Arterioscler Thromb Vasc Biol | 2013 | https://conductscience.org/library/papers/23640482 | PubMed |
| 13 | 11704864 | Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. | Oncogene | 2001 | https://conductscience.org/library/papers/11704864 | PubMed |
| 14 | 19319144 | The role of TNF superfamily members in T-cell function and diseases. | Nat Rev Immunol | 2009 | https://conductscience.org/library/papers/19319144 | PubMed |
| 15 | 37399355 | Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37399355 | PubMed |
| 16 | 25317870 | Chimeric antigen receptor T cells for sustained remissions in leukemia. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25317870 | PubMed |
| 17 | 25319501 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. | Lancet | 2015 | https://conductscience.org/library/papers/25319501 | PubMed |
| 18 | 28928126 | Chimeric antigen receptor T-cell therapies for multiple myeloma. | Blood | 2017 | https://conductscience.org/library/papers/28928126 | PubMed |
| 19 | 9325300 | Purification and characterization of the human interleukin-18 receptor. | J Biol Chem | 1997 | https://conductscience.org/library/papers/9325300 | PubMed |
| 20 | 34878825 | Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. | Sci Transl Med | 2021 | https://conductscience.org/library/papers/34878825 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42894261 | Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies. | Cancer Sci | 2026 | https://conductscience.org/library/papers/42894261 | PubMed |
| 42703556 | Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42703556 | PubMed |
| 42681665 | Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. | Biomark Res | 2026 | https://conductscience.org/library/papers/42681665 | PubMed |
| 42527665 | Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives. | Leukemia | 2026 | https://conductscience.org/library/papers/42527665 | PubMed |
| 42463973 | Interleukin-18 armours antitumour immune effectors. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42463973 | PubMed |
| 42093982 | Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42093982 | PubMed |
| 41899506 | Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899506 | PubMed |
| 41865195 | Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41865195 | PubMed |
| 41817579 | The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy. | Cancer Res | 2026 | https://conductscience.org/library/papers/41817579 | PubMed |
| 41792262 | Progress in the development of cytokine armoured CAR T cells. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/41792262 | PubMed |
| 41751464 | IL-18-Mediated Tumor Immune Evasion. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/41751464 | PubMed |
| 41728085 | How can we balance risk and benefit of interleukin-18 armored T cell therapies? | Exp Biol Med (Maywood) | 2026 | https://conductscience.org/library/papers/41728085 | PubMed |
| 41631887 | Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41631887 | PubMed |
| 41562052 | Serologic IL-18 increase with B-cell IL-18R loss characterizes selective IgA deficiency. | Front Immunol | 2025 | https://conductscience.org/library/papers/41562052 | PubMed |
| 41520178 | IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. | Mol Ther | 2026 | https://conductscience.org/library/papers/41520178 | PubMed |
| 41485186 | Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41485186 | PubMed |
| 41419929 | Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41419929 | PubMed |
| 41415362 | Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma. | bioRxiv | 2025 | https://conductscience.org/library/papers/41415362 | PubMed |
| 41131610 | CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future. | J Transl Med | 2025 | https://conductscience.org/library/papers/41131610 | PubMed |
| 40973858 | Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control. | Immunol Res | 2025 | https://conductscience.org/library/papers/40973858 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
| TNFRSF17 | 608 | PubTator's text mining | https://conductscience.org/library/genes/608 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38579288
GET https://conductscience.org/api/papers/v1/38579288/references?page=2